DexCom, Inc. (DXCM) Position Lifted by Dupont Capital Management Corp

Dupont Capital Management Corp boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 22.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,662 shares of the medical device company’s stock after acquiring an additional 1,560 shares during the period. Dupont Capital Management Corp’s holdings in DexCom were worth $424,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in DXCM. Winslow Capital Management LLC acquired a new position in DexCom during the second quarter worth $117,451,000. State Street Corp lifted its stake in DexCom by 2.5% during the second quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock worth $113,374,000 after purchasing an additional 37,581 shares in the last quarter. BNP Paribas Arbitrage SA lifted its stake in DexCom by 111.6% during the second quarter. BNP Paribas Arbitrage SA now owns 9,471 shares of the medical device company’s stock worth $693,000 after purchasing an additional 4,995 shares in the last quarter. Peregrine Capital Management LLC lifted its stake in DexCom by 24.5% during the third quarter. Peregrine Capital Management LLC now owns 395,455 shares of the medical device company’s stock worth $19,348,000 after purchasing an additional 77,868 shares in the last quarter. Finally, Macquarie Group Ltd. lifted its stake in DexCom by 67.2% during the second quarter. Macquarie Group Ltd. now owns 242,598 shares of the medical device company’s stock worth $17,746,000 after purchasing an additional 97,479 shares in the last quarter.

In related news, EVP Richard Doubleday sold 1,635 shares of the stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $75.26, for a total value of $123,050.10. Following the transaction, the executive vice president now owns 72,395 shares of the company’s stock, valued at $5,448,447.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Steven R. Altman bought 10,000 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was acquired at an average cost of $49.61 per share, for a total transaction of $496,100.00. Following the acquisition, the director now directly owns 4,353 shares of the company’s stock, valued at $215,952.33. The disclosure for this purchase can be found here. Insiders sold 13,964 shares of company stock worth $948,039 in the last three months. 1.70% of the stock is currently owned by corporate insiders.

A number of research firms have commented on DXCM. BMO Capital Markets restated an “outperform” rating and set a $90.00 price target (down from $105.00) on shares of DexCom in a research note on Wednesday, August 2nd. ValuEngine upgraded DexCom from a “sell” rating to a “hold” rating in a research note on Monday, November 6th. Northland Securities restated a “hold” rating and set a $50.00 price target on shares of DexCom in a research note on Thursday, November 2nd. BidaskClub upgraded DexCom from a “strong sell” rating to a “sell” rating in a research note on Wednesday, August 9th. Finally, Piper Jaffray Companies restated a “buy” rating and set a $87.00 price target on shares of DexCom in a research note on Thursday, September 28th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have given a buy rating to the company’s stock. DexCom has an average rating of “Buy” and an average target price of $70.69.

COPYRIGHT VIOLATION WARNING: This story was published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/11/13/dexcom-inc-dxcm-position-lifted-by-dupont-capital-management-corp.html.

DexCom, Inc. (DXCM) opened at $50.74 on Monday. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. DexCom, Inc. has a twelve month low of $42.62 and a twelve month high of $88.80.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply